A best evidence topic in cardiac surgery was written according to a structured protocol. The question addressed was whether transcatheter aortic valve-in-valve replacement (viv-TAVR) or redo aortic valve replacement (rAVR) is the best strategy in a patient with a degenerative bioprosthetic aortic valve. Altogether, 162 papers were found using the reported search, of which 12 represented the best evidence to answer the question. The authors, journal, date, country of publication, patient group, study type, outcomes and results of papers are tabulated. The results of the studies provided interesting results. All the studies are retrospective. Four papers reported the results of redo aortic valve replacement in patients with failed aortic bioprosthetic valve, six papers demonstrated their results with transcatheter aortic valve-in-valve replacement for the same indication and two papers reported their propensity-matched analysis of outcomes between viv-TAVR and rAVR in patients with previous cardiac surgery. Thirty-day mortality for rAVR was 2.3-15.5% and 0-17% for viv-TAVR. For rAVR, survival rate at 30 days was 83.6%, 76.1% at 1 year, 70.8% at 3 years, at 51.3-66% at 5 years, 61% at 8 years and 61.5% at 10 years. For viv-TAVR, the overall Kaplan-Meier survival rate at 1 year was 83.2%. After viv-TAVR at 1 year, 86.2% of surviving patients were at New York Heart Association (NYHA) class I/II. The complications after rAVR were stroke (4.6-5.8%), reoperation for bleeding (6.9-9.7%), low-cardiac output syndrome (9.9%) whereas complications after viv-TAVR at 30 days were major stroke (1.7%), aortic regurgitation of at least moderate degree (25%), new permanent pacemaker implantation rate (0-11%), ostial coronary obstruction (2%), need for implantation of a second device (5.7%) and major vascular complications (9.2%). It is noteworthy to mention that there is a valve-in-valve application that provides information to surgeons for choosing the correct size of the TAVR valve. Transcatheter aortic valve-in-valve procedures are clinically effective, at least in the short term, and could be an acceptable approach in selected high-risk patients with degenerative bioprosthetic valves. Redo AVR achieves acceptable medium and long-term results. Both techniques could be seen as complementary approaches for high-risk patients.
INTRODUCTION
A best evidence topic was constructed according to a structured protocol. This is fully described in ICVTS [1] .
THREE-PART QUESTION
In [a patient with a degenerative bioprosthetic aortic valve] is [transcatheter aortic valve-in-valve replacement or redo aortic valve replacement] the best strategy in order to optimize [event-free survival]?
CLINICAL SCENARIO
A 78-year old patient, with a history of previous aortic valve replacement with a bioprosthetic valve 20 years ago, comes to your office.
The patient has become increasingly dyspnoeic during the last year. Transthoracic echocardiography and transoesophageal echocardiography revealed severe aortic regurgitation (three-fourth). The valve has to be replaced. There are two options for the patient: transcatheter aortic valve-in-valve replacement or redo AVR.
SEARCH STRATEGY
A review of the English language literature was performed on Medline using the Ovid interface from 1980 to July 2014 [transcatheter aortic valve implantation OR transcatheter aortic valve replacement OR transcatheter aortic valve-in-valve procedure OR re-replacement of aortic valve OR redo aortic valve replacement) AND ( previous aortic valve replacement OR degenerative bioprostheses)]. 
SEARCH OUTCOME
Using the reported search, 162 papers were identified of which 12 papers provided the best evidence to answer the question. These papers are summarized in Table 1 .
RESULTS
Eitz et al. [2] showed that perioperative mortality rate was 15.5% in reoperations of the aortic valve in a group of 71 octogenarians. Indications for surgery were structural valve deterioration (76.1%), paravalvular leak (4.2%) and prosthetic valve endocarditis (11.3%). Survival rates at 30 days, 1 year, 3 years and 5 years were 83.6, 76.1, 70.8 and 51.3%, respectively. Estimated median survival was 5.6 years for patients with reoperations. Mid-term survival was similar when compared with a group of patients matched for age, gender and date of operation, having their first AVR. Davierwala et al. [3] showed that mortality rate was 4.6% in rAVR in 216 patients. The proportion of patients that received mechanical valves was 52% in the rAVR group, significantly higher than that in the first AVR operation in the same group of patients (17%). Reoperative aortic valve surgery was not a significant predictor of hospital mortality. There was a trend towards a decreased 30-day mortality following r-TAVI Kempfert et al. [4] showed that 30-day mortality was 0% in viv-TAVR in 11 patients. Stroke rate and new pacemaker implantation rate was 0%. Postoperatively, trans/paravalvular leak of first degree was 18.2% and mean AV gradient was 11 ± 4 mmHg.
Leontyev et al. [5] demonstrated that early mortality was 4.5% for all rAVR in 155 patients. Indications for redo AV surgery were endocarditis (27.1%), paravalvular leak (18.1%), bioprosthetic structural valve deterioration (16.1%), endocarditis with root abscess (14.2%) and bioprosthetic degeneration (7.7%). Five-and 8-year survival was 66 ± 5% and 61 ± 6%, respectively.
Eggebrecht et al. [6] showed that 30-day mortality was 17% in 47 patients that underwent viv-TAVR. Indications for surgery were isolated stenosis (47%), regurgitation (32%) and mixed stenosis and regurgitation (21%). Increased transvalvular gradients ≥20 mm were observed in 44% of patients, especially in those with bioprostheses of small diameters. Vascular access complications occurred in 13% of patients. New pacemaker implantation rate was 11%.
Pasic et al. [7] showed that operative mortality was 0% in 14 patients that were treated with viv-TAVR. Mean aortic transvalvular gradient decreased from 37.1 ± 25.7 mmHg to 13.1 ± 6.4 mmHg, postoperatively. There was no postoperative valve insufficiency. Up to 20 months postoperatively, 86% of patients were in New York Heart Association (NYHA) class I or II.
Bapat et al. [8] found that 30-day mortality was 0% in 14 patients that were treated with viv-TAVR. Indication for surgery was predominantly aortic valve stenosis (56%). Mean AV gradient decreased from 31.2 ± 17.06 mmHg to 9.13 ± 4.9 mmHg. Late death rate during the follow-up was 13%.
Linke et al. [9] showed that all-cause mortality at 30 days was 7.4% in a group of 27 patients that were treated with viv-TAVR. Major stroke rate was 3.7% and major access site complications were 11.1%. Survival rate at 6 months and 1 year was 92 and 88%, respectively. Mean AV gradient decreased from 42 ± 15 to 10 ± 8 mmHg.
Pechlivanidis et al. [10] demonstrated that hospital mortality was 2.3% in reoperations of the aortic valve in 131 patients. Ten-year survival was 61.5 ± 8.6%. Ten-year freedom from acute heart failure, reoperations, stroke and thromboembolisms were 62.9 ± 6.9%, 97.8 ± 1.5%, 93.2 ± 3% and 91.2 ± 3.2%, respectively. Redo AVRs achieved good results for elective cases, cases without endocarditis and NYHA class I/II cases.
Wilbring et al. [11] showed that 30-day mortality was 9.4% in a group of 53 patients who were treated with viv-TAVR versus 5.7% in a propensity-matched group of 53 patients who were treated with conventional redo AVR. Survival at 6 months was 83% in the viv-TAVR group vs 86.8% in the rAVR group. Mean grade of paravalvular regurgitation was 0.8 ± 0.2 in the viv-TAVI group vs 0% in the rAVR group.
Dvir et al. [12] showed that 30-day mortality was 7.6% in viv-TAVR in their international registry of 459 patients. Modes of aortic bioprosthesis failure were stenosis (39.4%), regurgitation (30.3%) and combined (30.3%). Major stroke rate was 1.7% and permanent pacemaker implantation rate was 8.3%. Overall 1-year Kaplan-Meier survival rate was 83.2%. Patients in the stenosis group had worse 1-year survival (76.6%) in comparison with the regurgitation group (91.2%) and the combined group (83.9%). Patients with small valves had also worse 1-year survival (74.8%) versus patients with intermediate-sized valves (81.8%) and patients with large valves (93.3%).
Papadopoulos et al. [13] showed that 30-day mortality was 8% in the viv-TAVR group versus 16% in the r-AVR group by using propensity analysis of matched subgroups of 40 patients. Actuarial survival at 4 years was 75 ± 3% in the viv-TAVR group vs 73 ± 4% in the rAVR group. Kaplan-Meier estimates of major adverse events (death and permanent neurological deficits) at 4 years were 25% for the viv-TAVR group vs 43% for the rAVR group.
CLINICAL BOTTOM LINE
Both viv-TAVR and rAVR provided good clinical results in high-risk patients with previous cardiac surgery. Both techniques could be seen as complementary approaches. An interdisciplinary heart team is necessary to discuss every patient and choose the best individualized approach.
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